Abrocitinib
B7451031
Phase 3 small_molecule active
Quick answer
Abrocitinib for Moderate-to-Severe Atopic Dermatitis is a Phase 3 program (small_molecule) at Pfizer Ireland Pharmaceuticals Unlimited Company with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pfizer Ireland Pharmaceuticals Unlimited Company
- Indication
- Moderate-to-Severe Atopic Dermatitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active